Pros And Cons Of Pfizer

Pharmaceutical companies are very important in society and the environment

surrounding us. It is an industry that needs to be taken care of day to day. Pfizer is the

world’s largest pharmaceutical company by total revenue and AstraZenica is number eight.

The proposed merger would create a company that would dwarf all its competitors. In this

report we will evaluate the pros and cons concerning the factors influencing the merger. We

will take a look at the following forces that will play a role in influencing the strategy of the

organization: the industry, the environment, stakeholder influence, and business idea.

The Industry

Pfizer is an American company that focuses on neurology, endocrinology,

immunology, oncology, cardiology, and diabetes while AstraZenica a British-Swedish

company that focus on oncology, cardiology, gastrointestinal, infection, neuroscience,

respiratory and inflammation issues. Both companies have a strong core of strategies to

outpace its rivals.

Pfizer spends billions worldwide on research and testing their new products to

make sure that they are the most advanced product on the market. Part of the company’s

strategy to drive away new entrants on the market is the introduction of a second brand, a

generic line to compete with itself. Pfizer Portfolio goes from the most advanced treatment

on cancer to healthcare products like ChapStick. Having a Pfizer line and its generic brand on

the market is one of the best strategies of the company to limit the competition of potential

action of producers of substitutes products since on the head of many of its loyal consumers

they would go for Pfizer second line that someone else that do not know yet. The marketing

strategy is that...

... middle of paper ...

... AstraZenica, beacuse Phizer wanted to require AstraZenica folders increase their

research and development capablity making the company further in their the differentiation

strategy, but unfortunately, the latest development showed that AstraZenica turned down the the

current proposal, because the investment money was not enough, and the pressure from the

stakeholder as well as the political system and the human resources.

Citations

AstraZenica. (2013). AstraZenica Annual Report and Form 20-F Information 2013. Retrieved

from http://www.AstraZenica.com/annualreport2013

Martins, A. J. (n.d.). Business Ideas vs. Business Opportunities: What is the difference?

Retrieved from http://www.mytopbusinessideas.com/ideas-vs-opportunities/

Pfizer Inc. (2013). 2013 Financial Report. Retrieved from

http://www.pfizer.com/investors/financial_reports/financial_reports